Targets › TACC3
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.
Plays a role in the microtubule-dependent coupling of the nucleus and the centrosome. Involved in the processes that regulate centrosome-mediated interkinetic nuclear migration (INM) of neural progenitors (By similarity). (UniProt, Q9Y6A5)
Open in Phaseline: the race on TACC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| A2A Pharmaceuticals | AO-252 TACC3 protein-protein interaction (PPI) inhibitor | TACC3 | Phase 1 | Solid Tumor Malignancies | Jan 2027 |
Solid Tumor Malignancies (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.